Development
Lexicon Pharmaceuticals, Inc.
LXRX
$1.05
-$0.07-6.25%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 162.00K | 317.00K | 24.00K | 28.00K | 39.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 162.00K | 317.00K | 24.00K | 28.00K | 39.00K |
| Cost of Revenue | 17.57M | 14.55M | 12.03M | 13.98M | 10.56M |
| Gross Profit | -17.40M | -14.23M | -12.00M | -13.95M | -10.52M |
| SG&A Expenses | 32.23M | 30.01M | 19.14M | 16.33M | 12.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.79M | 44.56M | 31.17M | 30.31M | 23.13M |
| Operating Income | -49.63M | -44.24M | -31.14M | -30.28M | -23.10M |
| Income Before Tax | -50.53M | -44.90M | -31.93M | -30.49M | -23.39M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.53M | -44.90M | -31.93M | -30.49M | -23.39M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.53M | -44.90M | -31.93M | -30.49M | -23.39M |
| EBIT | -49.63M | -44.24M | -31.14M | -30.28M | -23.10M |
| EBITDA | -49.48M | -44.10M | -31.03M | -30.18M | -22.99M |
| EPS Basic | -0.21 | -0.22 | -0.17 | -0.16 | -0.13 |
| Normalized Basic EPS | -0.13 | -0.14 | -0.11 | -0.10 | -0.08 |
| EPS Diluted | -0.21 | -0.22 | -0.17 | -0.16 | -0.13 |
| Normalized Diluted EPS | -0.13 | -0.14 | -0.11 | -0.10 | -0.08 |
| Average Basic Shares Outstanding | 244.93M | 204.78M | 189.01M | 188.73M | 174.90M |
| Average Diluted Shares Outstanding | 244.93M | 204.78M | 189.01M | 188.73M | 174.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |